A token-powered research engine for drug repurposing.

DeCure connects AI search, molecular compute, wet-lab validation and open publication. $DECURE coordinates the work.

A computational result can earn attention. Only experimental evidence can earn confidence.

Fixed supply of 1 billion $DECURE, minted once and launched on the open market.
No presale, no private round, no team allocation.
Trading fees: up to half to stakers, paid in SOL · half to the research: $150K per DeCure: $50K in silico · $50K PhD & paper · $50K in vitro.
Proof-of-Folding, staking and research routing are later modules. Each ships with its own public status and official address.
Official mint, pool and program addresses are published on the Addresses page when they are live.

The protocol

DeCure searches approved medicines for new uses. AI maps the biology, structured evidence ranks the candidates, Proof-of-Folding models the strongest drug–target pairs on the protocol’s own hardware, a real laboratory tests what survives, and the evidence is published open-access.

5,000

diseases mapped across 12 research labs

fixed supply — minted once, open-market launch

50 / 50

trading fees: community · research · stakers get up to half, in SOL

01The problem

A promising new use for an existing medicine can be scientifically worth testing and still have no obvious path to funding. The molecule may be generic, second-use protection may be narrow, the disease may be rare, or the first experiment may be too early for commercial capital and too applied for a conventional academic grant. The bottleneck is often not the science. It is who pays for the experiment that settles the question.

02The idea

DeCure is built for that gap. AI maps disease biology and proposes candidates across thousands of diseases, structured evidence ranks them independently of the language model, the protocol folds the strongest drug–target pairs, and a qualified laboratory runs the assay that can falsify the hypothesis. Methods, raw data and analysis are published either way. A well-executed negative result closes a path and improves the next decision.

03Proof-of-Folding

Proof-of-Folding is the protocol’s molecular screening step. Instead of burning energy on arbitrary hashes, the compute runs our AI co-folding model to model how a candidate drug binds a disease target. $DECURE funds the work, and every run and its score go into the weekly research report. A strong fold is evidence about whether the next experiment is worth running. It is not the experiment itself.

Discovery

AI scientists propose approved-drug → disease candidates

Folding

our AI scores binding on the protocol cluster; results published weekly

Wet-lab

top candidates tested in a real laboratory ($150K per DeCure: $50K in silico · $50K PhD & paper · $50K in vitro)

Open paper

results published open-access as a citable preprint

04The 12 labs

Research is organized into 12 autonomous AI-scientist labs — one per disease area — collectively covering 5,000 real diseases, many with no approved therapy today (the "white space" where the need is greatest).

Cancer · Neuro · Psychiatry · Cardio · Respiratory · Nephrology · Dermatology · Metabolic · Immuno · AMR · Longevity · Rare & Orphan.

05$DECURE — the token

$DECURE is a vote on the research: staking chooses which of the twelve labs gets more compute, and committing chooses which disease goes to the lab first. Fixed supply, minted once, with no presale and no team allocation. It carries no equity, dividend, royalty or claim on a paper, patent or laboratory, and it can lose all value.

Property	Design
Launch	Fair launch on Solana — no presale, no insiders
Allocation	100% open market · no presale, no team, no reserve
Trading fees	up to 50% to stakers, paid in SOL · 50% to the research ($150K per DeCure: $50K in silico · $50K PhD & paper · $50K in vitro)
Staking	Vote on the twelve labs and share up to half of every trading fee, paid in SOL; claim it in DeGame or use it to buy back & burn $DECURE; exit in seven days
Commitment	Point tokens at one DeCure; the longer they stay, the more weight they carry

Two ways to take part

Action	You choose	Time
Stake	One of the twelve labs	Exit in 7 days
Commit	One DeCure	Weight grows over a year

How staking directs the science

Your weight, your split — a staking position divides its vote across the twelve research areas as you choose; committing to a DeCure adds weight to that one disease.
Bounded outcomes — each lab receives at least 5% and at most 40% of a research allocation epoch, so attention can move without any single field taking everything.
Evidence decides — stakers choose where attention goes. Whether a result is true is settled in a laboratory, not by a vote.

06Governance

A light, on-chain DAO — scope limited to steering the protocol, not a legal entity. Stake-weighted voting sets the allocation across the 12 labs, each bounded to a 5–40% share. Longer commitments carry more weight, and the 5% floor plus the 40% cap keep any single holder from buying the outcome.

07The mission

The ambition is deliberately large: to channel up to $1 trillion into real drug-repurposing research, published in the open, and to make researching a neglected disease something a global community can fund and direct together. "Trillion-dollar" is the size of the mission — not a price target, forecast, or promise about the token.

Risks

The honest version.

$DeCure may lose its value in part or in full, and there is no mechanism and no party obliged to prevent that.
It may not always be transferable, and it may not be liquid.
It may never be exchangeable for anything, in particular if the project is discontinued.
It is covered by no investor compensation scheme and no deposit guarantee scheme, because it is not a financial instrument or a deposit.
Nobody is responsible for making the project succeed and nobody can be compelled to continue it.

Scientific risk

Drug repurposing has a high failure rate. Most candidates will not become therapies.
The prioritisation engine's measured discriminative signal is weak: held-out AUROC 0.60 (95% CI 0.578–0.622; n = 2,708 pairs, 455 diseases; label-shuffle control 0.50). It is published with its interval and shuffle control precisely so it is not mistaken for predictive certainty.
Prior human exposure to an approved drug removes no requirement for dose, route, population, combination or new preclinical and clinical work in a new indication.
Repurposed generics carry weak or fragmented exclusivity — the reason the field is under-financed, and a constraint on the protocol's own sustainability.
Peer review is outside anyone's control and cannot be guaranteed on any timeline.

Technical and structural risk

Nothing is deployed. There is no assurance the protocol will be built, deployed or work as described.
Unaudited code, key management failure, irreversible transactions.
Dependence on a single third-party blockchain, including outages, congestion, forks and validator concentration.
Regulatory risk: the treatment of the asset in any jurisdiction may change, and the position set out above may be rejected.

Current state

Component	Status
Disease catalogue	Live — 5,000 pages across the 12 labs
Evidence pipeline	Operating — retrieval over 234,678,978 indexed works, experimental structure resolution, relationship-direction audit
Verified drug–disease pairs	397 pages, 525 pairs, corroborated in primary literature and audited for relationship direction
Prioritisation engine	Held-out AUROC 0.60 (95% CI 0.578–0.622)
Proof-of-Folding program	Coming soon
Token	Coming soon — no mint address exists
Network	Coming soon
Wet-lab validation	Coming soon
Peer-reviewed publications	Coming soon

Disease pages and model outputs are research, not medical advice, and no claim is made that a treatment exists for any disease. $DECURE confers no equity, dividend, royalty or claim on a paper, patent, dataset or laboratory. Most candidates fail in the lab. Research outcomes are never guaranteed and $DECURE can lose all of its value.

Protocol paper v1 · Token stack · Disease catalogue · Project